Lilly moves toward psoriasis showdown with Novartis in EU

Look out, Novartis ($NVS). Eli Lilly ($LLY) is now one step closer in the EU to challenging the Swiss pharma's new psoriasis standout, Cosentyx, with its own next-gen therapy, ixekizumab. The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has backed a go-ahead for the therapy, and regulators typically green-light recommended approvals within three months. More from FierceBiotech

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.